首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Frontiers In Immunology

Frontiers In Immunology杂志,由Frontiers Media S.A.出版,于2010年创刊,1 issue/year,出版语言English,ISSN:1664-3224,E-ISSN:1664-3224。

投稿咨询
Frontiers In Immunology
Frontiers In Immunology
Frontiers In Immunology
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
7
CiteScore
11.3
期刊收录
SCI、SCIE

Frontiers In Immunology(中文译名:《免疫学前沿》),ISSN:1664-3224,EISSN:1664-3224,是Frontiers Media S.A.出版的国际性学术期刊,创刊于2010年,以1 issue/year形式稳定发行,2026年总发文量约6551篇。该刊采用OA开放访问,学科归属为IMMUNOLOGY。该刊是医学、免疫学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达7,2025年期刊CiteScore为11.3,2025年期刊自引率约7.1%,在中科院期刊分区体系中位列医学大类2区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Frontiers In Immunology长期聚焦医学、免疫学及相关产业的技术应用前沿,平均审稿周期14 Weeks,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、免疫学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、GERMANY (FED REP GER)、England、Italy、France、Netherlands等为核心发文国家与地区;INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)、UNIVERSITY OF LONDON、HARVARD UNIVERSITY、UNIVERSITY OF CALIFORNIA SYSTEM、UNIVERSITY OF OXFORD、HELMHOLTZ ASSOCIATION等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
IMMUNOLOGY 免疫学
2区
是 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
IMMUNOLOGY 免疫学
2区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
IMMUNOLOGY 免疫学
2区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:IMMUNOLOGY SCIE Q1 29 / 183

84.4

学科:IMMUNOLOGY SCIE Q1 42 / 183

77.32

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:IMMUNOLOGY SCIE Q1 38 / 181

79.3

学科:IMMUNOLOGY SCIE Q1 43 / 181

76.52


中国学者近期发文

1
The glycolysis-lactylation axis: a metabolic-epigenetic driver of immunosuppression and therapy resistance in cance

Author:Tan, Simin; Zhang, Weijia; Ding, Yuqing; Liu, Jinlin; Zhu, Min; Luo, Xuefeng; Cai, Jun; Zeng, Hai

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1772701

2
Biofilm adaptation and mucosal immune dysregulation in recalcitrant chronic rhinosinusitis: from pathogenesis to a therapeutic roadma

Author:Tan, Shiwang; Lai, Ju; Yu, Shaoqing

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1797096

3
Efgartigimod as a potential alternative to intravenous immunoglobulin in Guillain-Barré syndrome: a retrospective stud

Author:Liu, Changyue; Wang, Kaiyue; Zhang, Shimeng; Gao, Naiyong; Xu, Guangyin; Qi, Faying

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1734853

4
Efficacy and safety of efgartigimod in very-late-onset myasthenia gravi

Author:Zhao, Yunbin; Qu, Meijie; Rong, Xi; Sun, Xupeng; Wang, Li; Liu, Min; Sui, Jiaona

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1808357

5
Overcoming immune resistance in hepatocellular carcinoma: insights into mechanisms, predictive factors, and interventional strategie

Author:Wang, Zhenxao; Wu, Jun; Li, Qiao; Wen, Xin

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1804366

6
Case Report: Ultrasound features of pathological complete response in middle and low rectal cancer with high microsatellite instability after neoadjuvant immunotherapy: a case serie

Author:Liang, Li; Wang, Qi; Chen, Yifeng; Zhang, Xinhua; Zhou, Zubang; Nie, Fang

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1772953

7
From centripetal to centrifugal: pathological regression patterns after neoadjuvant or conversion therapy as markers of nodal risk and a framework for future research on individualized lymphadenectomy in gastric cance

Author:Li, Na; Liu, Penghui; Guo, Jiwu; Wang, Jizhen; Zhao, Gengyutong; Mou, Ziyuan; Mao, Jie

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1766242

8
Decoding the immune microenvironment: precision immunotherapy for medulloblastoma subtype

Author:Li, Mengyuan; Peng, Jihong; Chen, Chun; Hu, Jinyang

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1714134

9
Durable response to FOLFOX plus serplulimab in AFP-producing gastric adenocarcinoma with liver metastases: a case report and literature revie

Author:Jin, Yuqi; Fu, Linglin; Zhao, Yuhan; Tong, Ziyan; Tan, Yinuo

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1795732

10
Targeted regulation of adipose tissue macrophages from an immunometabolic perspective: a novel therapeutic approach for obesity-related metabolic disorder

Author:Jia, Chen; Wu, Enfang; Zhu, Chenjia; Guan, Xiyuan; Cheng, Yuqi; Zhao, Feng; Jin, Xin; Cao, Dan; Li, Xueyu

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1803488


在线咨询

Frontiers In Immunology

国际简称:FRONT IMMUNOL参考译名:免疫学前沿

年发文量:6551 CiteScore:11.3 是否预警:否 Gold OA文章占比:99.90% 研究类文章占比:69.99%

杂志社联系方式:AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, SWITZERLAND, CH-1015

Frontiers In Immunology